23 May 2017 | News
High Court of Delhi Grants Permanent Injunction Against the Manufacture and Sale of Sinopharm Weiqida Pharmaceutical’s Amoxicillin Active Pharmaceutical Ingredient in India
DSM Sinochem Pharmaceuticals (DSP) which is the global leader in production and commercialization of sustainable, enzymatic antibiotics, next generation statins and anti-fungals recently announced that the High Court of Delhi has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical for patent infringement in India.
According to DSM Sinochem Pharmaceuticals’ (DSP) wholly owned subsidiaries, DSM Sinochem Pharmaceuticals Netherlands B.V. and DSM Pharmaceuticals India Pvt. Ltd., the High Court of Delhi, India, has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical Co., LTD ("Weiqida") for patent infringement of Indian Patent Number 247,301. This patent, which is owned by DSP, relates to amoxicillin trihydrate having a low free water content and processes for the manufacture thereof.
The permanent injunction prevents the manufacture, use, importation, offering for sale and sale of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India, as well as any drug product that utilizes the active pharmaceutical ingredient.
Karl Rotthier, CEO at DSP said, “DSP welcomes the Court’s decision, The lawsuit is intended to protect DSP’s world class intellectual property portfolio relating to our innovative, sustainable, and environmental friendly amoxicillin technology. DSP will continue to rigorously enforce its IP assets worldwide as it continues to invest in its innovative R&D programs directed to enzymatic, sustainable antimicrobials and statins.”